Citadel Advisors’s BioVie BIVI Stock Holding History

Citadel Advisors’s Portfolio BIVI Stock Details BIVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$63.4K	Buy	45,292 +27,142	+150%	+$34.9K	﹤0.01%	12301
2025 Q4	$21.1K	Sell	18,150 -86,381	-83%	-$139K	﹤0.01%	12334
2025 Q3	$199K	Buy	+104,531	New	+$423K	﹤0.01%	11275
2024 Q1	–	Hold	0	–	–	–	14569
2023 Q4	–	Sell	-81	Closed	-$24.3K	–	14154
2023 Q3	$27.5K	Buy	+81	New	+$31.7K	﹤0.01%	12359
2023 Q2	–	Sell	-16	Closed	-$10.8K	–	14349
2023 Q1	$12.9K	Sell	16 -136	-89%	-$90.1K	﹤0.01%	13385
2022 Q4	$118K	Buy	+152	New	+$82.2K	﹤0.01%	10990

Other funds holding BIVI

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PTC

Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors's BIVI Position: Q1 2026 in Review

Citadel Advisors increased its BioVie (BIVI) stake by 150% in Q1 2026, buying an estimated $34.9K and bringing the position to 45,292 shares worth $63.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12301.

Citadel Advisors first reported a position in BIVI in Q4 2022 and has held it in 6 quarters since. The position peaked at $199K in Q3 2025. 33 funds tracked by Wall St. Rank hold BIVI as of Q1 2026.

Citadel Advisors held 45,292 shares of BioVie worth $63.4K as of Q1 2026.
Citadel Advisors bought 27,142 BioVie shares in Q1 2026, an estimated $34.9K.
BioVie made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12301 holding.
Citadel Advisors first reported a position in BioVie in Q4 2022 and has held it in 6 quarters since.
Citadel Advisors's BioVie position peaked at $199K in Q3 2025.
33 funds tracked by Wall St. Rank held BioVie as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.